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The HIV/AIDS epidemic in the United States and globally has proved to be a major public 
health issue and a topic of medical, scientific, and epidemiologic research for almost four decades. 
The HIV/AIDS pandemic, now considered an ongoing epidemic, changed the way many countries 
deal with public health associated issues, putting into place prevention measures, surveillance and 
other practices to prevent the spread of the disease while continuing to educate the public. Human 
immunodeficiency virus, or HIV, causes impaired immune function and increased susceptibility 
to opportunistic pathogens, preventing proper immune response, especially in those with advanced 
stage HIV disease or in those with poor adherence to antiretroviral therapy (ART). As of 2021, 
coronavirus disease 19 (COVID-19) caused by a novel coronavirus known as severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly communicable and transmissible 
respiratory infection responsible for a deadly global pandemic. Immunocompromised individuals, 
such as those living with HIV, are most susceptible to COVID-19, potentially causing severe 
disease or death. Data collected by the Multicenter AIDS Cohort Study (MACS) and the Women’s 
Interagency HIV study (WIHS) during the height of the pandemic evaluated risk factors for HIV-
positive and HIV-negative participants.  This essay assesses the degree to which HIV infected 
individuals are at a higher risk for disease caused by the novel SARS-CoV-2 and whether a 
discrepancy exists between HIV-positive and HIV-negative individuals enrolled in the study. 
 v 
Investigation of potential differences between the groups could determine the relationship between 
HIV and COVID-19 and if coinfection influences outcomes. Further, susceptibly to COVID-19 
and public health infrastructure will be described, and other demographic and geographical 
relationships will be highlighted.  
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1.0 Introduction  
Emergence of SARS-CoV-2 in Wuhan, China, in late 2019 has caused an ongoing global 
pandemic responsible for over 149 million cases and an estimated 3.14 million deaths worldwide 
as of mid-2021, although these numbers may be underestimated (Quiros-Roldan, 2020). In the 
United States alone, 31.2 million cases have been reported with almost 600,000 deaths since 
January 2020, (1 World Health Organization [WHO], 2021). Rapid spread of the infection and 
lack of overall understanding of its virulent properties of the disease lead to an increase in 
pneumonia-like illness throughout the population (Vizcarra, 2020). The sudden increase in cases 
and deaths due to acute respiratory failure and diminished respiratory function overwhelmed 
hospital systems, causing employment of significant, widespread public health measures to protect 
vulnerable populations (Lucas, 2020).  Those of advanced age living with diabetes, cardiovascular 
disease or chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), 
asthma, emphysema, as well as immunocompromised individuals are most at risk for severe 
disease (Mirzaei, 2021). People living with human immunodeficiency virus (PLWH) are 
considered a vulnerable population, and may be at a higher risk for coinfection due to low immune 
cell counts or unsuppressed viral loads (Vizcarra, 2020). Factors that may contribute to increased 
susceptibility include, but are not limited to: age, BMI, male sex, poor adherence to public health 
guidelines and practices issued by global, federal, and local health agencies and departments, work 
assignments that increase exposure to others, failure to adhere to antiretroviral therapies as 
prescribed, educational and language barriers, and lack of resources such as food, transportation, 
financial support, and shelter (Inciarte, 2020). As of 2019, there are approximately 38 million 
people living with HIV-positive status worldwide, a cause of concern for a significant 
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immunocompromised population as COVID-19 continues spread (2 World Health Organization 
[WHO], 2021). Because information is scarce on HIV as a risk factor for COVID-19 due to its 
novel properties, initiation of preliminary studies may help to describe any significant association 
between these diseases. Recent publications vary in conclusive evidence, where, some early 
observational reports suggest presence of comorbidities and male sex increase overall morbidity 
of HIV-positive patients (Mirzaei, 2021). However, other studies with small sample sizes do not 
conclude excess mortality among hospitalized PLWH with COVID-19 infection, specifically in 
those on ART (Harter, 2020). Other research points to high ART adherence (≥ 95%) have better 
outcomes than those not taking or with poor adherence (<95%) to ART (Achappa, 2013; 
Ridgeway, 2020). These results are inconclusive and contradictory, indicating more data collection 
and larger sample sizes within cohort studies may provide tangible evidence, and help determine 
potential increased risk or mortality. Implementing further guidelines or defining at risk 
populations is critical to combatting death due to COVID-19, where consistency in the findings is 
necessary to addressing morbidity and mortality issues or lack thereof in those with HIV. 
1.1  Background of HIV/AIDS Epidemic  
Human deficiency virus, or HIV, specifically HIV-1, is a lentivirus responsible for causing 
acquired immunodeficiency syndrome (AIDS), a disease that has claimed over 33 million deaths 
since its identification in 1981. HIV-1 is a cross-species retrovirus that resulted from simian 
immunodeficiency virus in African primates, a direct result of SIVcpz dissemination via 
chimpanzees (Sharp, 2011). Invasion of host occurs through mucosal sites and most commonly 
via sexual transmission, especially of rectal surface mucosa. Other sites of entry include genital, 
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vaginal, gastrointestinal mucosa, as well as blood and placental transmission (Hladik, 2008). HIV 
targets proteins on immune cells to gain entry, specifically on membranes of CD4+ T lymphocytes 
or T cells, plasmacytoid dendritic cells (pDCs), myeloid dendritic cells (mDCs), and macrophages, 
eventually reducing total cell numbers and function of these cells. A decrease in immune cells and 
function result in low immune function, especially in advanced infection (Martinson, 2007). Thus, 
AIDS is clinically characterized by a T-cell count <200 uL, where continued depletion describes 
disease progression (CDC, 2015, Leda, 2020). Pathogenesis of HIV is long-term and persistent 
and infection effectively causes chronic compromised cell-mediated immunity if antiretroviral 
therapy (ART) is not employed long-term (Lucas, 2020). Overall weakening of the immune system 
results in infections by opportunistic pathogens due to decreased or absence of immune 
functionality, resulting in death (Hladik, 2008).  Emergence of HIV has resulted in a public health 
crisis officially being declared a global epidemic, where major health and global associations such 
as the World Health Organization and the United Nations have continued work to control and 
eventually eradicate the disease by 2030 (Lou, 2018). This has proved to be a challenge, though, 
as many low-income, developing countries have missed targets for testing, therapies, and have 
failed to promote HIV prevention through public health recommendations (WHO, 2021). 
Serologic testing and detection for HIV antibodies increases chances for HIV infected individuals 
to receive early interventions of antiretroviral therapies that increase reportable data and 
surveillance, while preventing transmission and population incidence. Rates of HIV tend to be 
higher in those participating in risky sexual behaviors with multiple partners, men who have sex 
with men (MSM) and injection drug users, and racial minorities especially in urban areas. 
HIV/AIDS incidence in MSM is higher than the general population, accounting for approximately 
40-60% of all cases (Fleming, 2004). Other vulnerable populations include young women and 
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pregnant and breastfeeding women in Southeast Africa, sex workers, and transgender people, 
accounting for all other new infections. However, 38 million current and new infections have been 
reported since 2019, despite new technologies and pharmaceutical advances and introductions, 
such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), making headway 
through ongoing efforts to eradicate the infection. Introduction of ART and combination 
antiretroviral therapies (cART) remains the most significant means to prevent progression to AIDS 
and expand life expectancy, where the majority of HIV patients can manage the disease with 
continued, lifetime ART adherence (WHO, 2021). 
 
1.2  COVID-19 
SARS-CoV-2 is an emergent, novel virus belonging to the family of coronaviruses causing 
upper and lower respiratory illness that infect humans and the cause of coronavirus disease in 2019 
(COVID-19) (Liu, 2020).  Isolation and tracing efforts determined the primary infection originated 
in an outdoor seafood market Wuhan, China. SARS-CoV-2 shows a similar receptor binding 
domain of the S gene (necessary for viral binding) to a bat betacoronavirus (RaTG13). It is also 
found that a potential recombination event occurred via Mongolian pangolin which may be the 
intermediate host reservoir for SARS-CoV-2, causing mutation and human infection. SARS-CoV-
2 infects human lung cells by binding to angiotensin converting enzyme 2 (ACE2) on the cell 
membrane, allowing fusion of the viral envelope (Abdel-Moneim, 2021, Millet, 2018). Although 
similar novel coronaviruses such as severe acute respiratory syndrome (SARS-CoV) and Middle-
Eastern respiratory syndrome (MERS-CoV) caused outbreaks in the past 20 years, with case 
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fatality rates less than 10% and less than 35%, respectively. Investigational reports show higher 
affinity (10-20%) ACE2 binding of the S protein in SARS-CoV-2 than in SARS-CoV, which may 
be a key factor for high transmission and mild to severe illness rates (Varghese, 2020). Thus, the 
COVID-19 outbreak caused a global pandemic, rapidly disseminating through China, and to the 
rest of the world within the first 60 days of identification (WHO, 2021).  
1.2.1  COVID-19 Transmission and Clinical Characteristics 
Viral exposure and transmission is understood to be via respiratory droplets and proximal 
contact of and with COVID-19 infected patients, both symptomatic and asymptomatic. Respiratory 
droplets produced through coughing or sneezing can be aerosolized and have the potential to reach 
up to 1 m if the droplets exceed 5 µm. Contamination of hands through surfaces can cause illness 
if there is contact with nasal or oral epithelium; droplets may live on surfaces or can be spread 
through fecal matter or urine in some cases. Transmission may take place most commonly in 
individuals with advanced age, underlying health issues and comorbidities, immunocompromised 
patients, and other vulnerable populations, where transmission directly increases with exposure 
time and proximity to infected individuals (Qu, 2020).  
The incubation period for COVID-19 is anywhere from 1-20 days, with 3-14 days being 
most common. Presentations of COVID-19 are described as pneumonia-like, with mild to severe 
respiratory illness. Other identifiable characteristics include (at onset): Fever, dry cough, fatigue, 
shortness of breath, and chills and body aches. Manifestations in more severe cases may include, 
but are not limited to: acute respiratory distress syndrome (ARDS), septic shock, and multiple 
organ failure caused by viral sepsis where fever did not present. Severe cases of COVID-19 
infection may also result in consolidation lesions in the lower lobes of the lungs and lung fibrosis, 
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lung tissue infiltration by monocytes and macrophages, and cytokine storm, inducing 
proinflammatory interleukin 6 (IL-6). Unusual laboratory findings in patients show decreased 
lymphocyte count at onset of disease (<1.0 x 109 /L), where, if levels increase the prognosis for 
critically ill patients shifts towards recovery. However, CD4+ T cells may determine prognosis, 
especially in severe cases. If T cell counts reach levels below 400/µL, prognosis and clinical 
outcome is poor especially in immunocompromised patients (Goyal, 2020, Qu, 2020).  
1.2.2  Implications of COVID-19 and Public Health Guidelines 
The COVID-19 global pandemic has been, and continues to evolve as a major public health 
issue. Due to the nature of the disease and almost no existing pharmaceutical treatments, the 
impacts of the virus are long-lasting, both economically and medically. Considered a health 
emergency, the COVID-19 pandemic was declared on March 11th, 2020. Negative impacts of the 
pandemic can be seen in almost all business, economic, and government sectors, damaging a $90 
trillion global economy (Jackson, 2020).  The responses to the crisis were rapid and employed with 
hasty decision making by government and public health officials, creating an unclear future and 
difficult environment to monitor and enforce adherence to changing guidelines (Hartley, 2020). 
Surveillance of the disease and contact tracing are potential life-saving, effective methods to 
prevent and contain disease and decrease mortality due to COVID-19 (Qu, 2020). Overall, public 
health interventions must be employed to vaccinate, eradicate, and reset the global economy. 
Prevention and non-pharmaceutical interventions (NPIs) are the easiest, and most cost-effective 
mode of controlling spread and containing the disease. Notably, quarantine practices, especially in 
those with increased susceptibility or proximity to infected patients is necessary to reduce risk for 
transmission. Self-quarantine prevents those potentially exposed to the virus from exposing others 
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(Qu, 2020). According to CDC recommendations, the length of quarantine is 14 days if close-
contact exposure exceeds 15 minutes, or after 10 days without symptoms or test, or after 7 days 
with a negative test result. These lengths are based off of the incubation period for COVID-19 and 
the typical onset of symptoms (CDC, 2020). Quarantine, isolation (if diagnosed with COVID-19), 
and “shelter-at-home” practice is found to be effective in cutting off transmission routes, and prove 
to be an effective prevention strategy (Pan, 2020).  
Other preventative strategies include the use of personal protective equipment (PPE), 
especially for medical and healthcare staff. PPE for high risk healthcare workers include the use 
of medical and fitted N-95 masks with optimal filtering efficiency (<95%), surgical masks, 
goggles, face shields, medical gowns, and gloves (Tcharkhtichi, 2021). Proper use of medical or 
non-medical masks or other protective face covering by non-healthcare workers in public spaces 
minimizes potential for infection and community spread by up to 79% (Wang, 2020). 
Discontinuing all social gatherings and school and work space environments where droplets 
containing virus can easily spread from person to person, maintaining a safe distance from others 
where droplets can not be inhaled (CDC recommendation of 6 feet) and continuous hygiene efforts, 
such as proper handwashing and use of alcohol-based sanitizer when hand washing is not possible 
are also prevention methods that have shown to decrease widespread disease (CDC, 2020). These 
strategies are essential to flatten the epidemiological curve of COVID-19, prevent severe disease 




1.3  HIV and COVID-19 
Risk for COVID-19 in relation to outcomes and infection rates among PLWH is not well 
characterized. Clinical outcomes for COVID-19 have shown to be more severe in those with 
comorbidities and preexisting conditions, especially for men, those in minority groups, individuals 
with a history of tobacco use, and high body mass indices (BMI) over 30 (Gervasoni, 2020; Hadi, 
2020). 
Limited COVID-19 outcomes have been collected specifically in patients with positive 
HIV status, although the CDC included caution for HIV positive status as a potential risk for severe 
illness in the COVID-19 risk reports (CDC, 2020). This is contributed to overall compromise in 
immune function in HIV positive individuals and increased comorbidities or multimorbidity in the 
identified population. Percentage of heart disease, diabetes, and kidney disease diagnosis is higher 
in patients with HIV than in other groups (Hadi, 2020; Nagarakanti, 2020). A review article 
published in January of 2021 reviews the first 6 months of the pandemic. The findings showed 
there was not a higher risk of mortality in PLWH especially with comorbidities and risk factors, 
however does not provide data on testing or the prevalence of positive diagnoses in the PLWH 
group (Johnston, 2021). Other studies have made the characterization that the daily use of class 
combination antivirals including nucleoside transcriptase inhibitors in addition to protease 
inhibitors (such as in consistent ART use by PLWH) could reduce the severity of disease, or even 
prevent illness (Cabello, 2020, Ridgeway, 2020). However, this report is not supported by 
substantiated inferences, nor are significant studies available to make this conclusive assessment 
(Patel, 2020). Thus, information on HIV status and COVID-19 diagnoses is insufficient, and 
further investigation is needed to have true predictors of morbidity and mortality in PLWH. 
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1.4  MACS/WIHS Cohort Study 
The Multicenter AIDS Cohort Study (MACS) started in 1983 at the beginning of the 
HIV/AIDS pandemic at the Johns Hopkins School of Public Health, expanding to 4 main 
investigative public health centers by 1986. The MACS continues in collaboration with the 
Women’s Interagency HIV Study (WIHS) to form the MACS/WIHS Combined Cohort Study 
(MWCCS). The study is funded through National Heart, Lung, and Blood Institute (NHLBI), and 
partially through other coordinating national institutes contributing to HIV research. As of 2011, 
the study has expanded to include over 100 investigators contributing to the research and data at 
the MACS. Investigators and contributors have successfully studied the natural history of AIDS, 
as well as genetic, behavioral, psychological, biological, virologic, and clinical implications, using 
quantifiable data and collected specimens from MSM participants. Participation in the MACS is 
based on MSM status, and surveys individuals with and without HIV positive status (De Jesus, 
2020, Detels, 2012). The longitudinal study involves almost 7000 participants nationally, with the 
largest centers concentrated in Los Angeles, Baltimore, Chicago, and Pittsburgh (De Jesus, 2020). 
A culmination of research continues to contribute to breakthrough discoveries in the field of 
HIV/AIDS as well as medicine, pharmaceuticals, sociology, and neuropsychology, and continues 
to recruit PLWH and reach those most vulnerable or at risk for HIV.  
1.4.1  COVID-19 Study 
The MWCCS launched a study in April of 2020 to document occurrences of COVID-19 in 
participants in the MACS and WIHS centers across the United States, concluding in September of 
2020. The study aimed to document any changes over time and patterns of COVID-19 testing and 
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availability, HIV status, adherence to mask use, social distancing, and other public health 
guidelines, variations in substance use and social behaviors prior to the pandemic, changes in 
resources or employment status, access to prescription medications, and food insecurity. This study 
collected qualitative data via phone interviews to investigate causal factors linked to COVID-19 
and HIV status, and whether HIV status and outside factors had an impact on COVID-19 infection 
rates among participants. 
1.4.2 Published Article on COVID-19 Study  
The article “COVID-19 symptoms and SARS-CoV-2 infection among people living with 
HIV in the US: the MACS/WIHS combined cohort study” by D’Souza, et al. published in HIV 
Research & Clinical Practice in November 2020 analyzes the data from the COVID-19 
investigation collected by the MWCCS. The article outlines SARS-CoV-2 infection among 
participants, as well as the demographic and geographic information collected by the survey, and 
analyzes positivity rates, associated risks, testing prevalence and reported participant symptoms 
from April 2020 until June 30, 2020. Using the data collected from the questionnaires, the article 
reports that 61% PLWH and 39% of seronegative (SN) eligible participants completed the 
interview. Utilizing collected information from the most recent visit to a site clinic, about 74% of 
PLWH had undetectable viral loads. The median age of participants was 57 years, where 46% 
were men and 54% were women. Other identified demographics include race, where 48% were 
Black non-Hispanic, 36% White non-Hispanic, 13% Hispanic, and 3% were of another racial 
category. 
It is important to note that about 98% of participants reported following stay-at-home orders and 
physical distancing from others. However, only 62% of participants reported utilization of a mask 
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in public. PLWH were more likely to report not changing lifestyle than seronegative participants, 
even after public health guidelines were established.  
The publication also focuses on symptom reporting by participants. Over half (53%) of 
participants experienced at least one symptom consistent with SARS-CoV-2 infection, however, 
SN participants were more likely to report having at least one symptom since January 2020. 
Of the 441 participants reporting testing for SARS-CoV-2 infection, 31 PLWH reported positive 
tests, compared to the 10 SN participants reporting positive tests. Of the PLWH participants, 94% 
were adhering to prescribed antiviral therapies. The study also highlights that 83% of participants 
did not seek out testing for a multitude of reasons including not having access to testing if 
experiencing symptoms before or at the time of the interview or being told by a healthcare provider 
to self-quarantine instead of getting tested.  The results described in the publication also conclude 
that PLWH had higher positivity rates in high density areas, such as New York City and Chicago. 
The paper also emphasizes that there was no significant difference between age and/or race and a 
positive SARS-CoV-2 test result. Thus, the adjusted odds ratio calculated in this paper defines the 
positivity rate in PLWH as marginally higher (95% CI =1.01-4.85, p=0.046) than in those without 
HIV diagnosis after adjusting for geographic location and household size. 
 The article by D’Souza et al. is crucial to understanding the background of the study, 
providing essential information about the MWCCS participant demographic, as well as 
supplementary data that supports the analysis outlined in this essay. However, the published work 
reports only on the data collected from baseline interviews, excluding data collected after June 30 
2020. This essay continues the analysis of positivity rates among PLWH during all interview 
waves from April until September 2020, and describes any change in SARS-CoV-2 testing or 
positivity rates. 
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Figure 1: MACS/WIHS (MWCCS) sites participating in the COVID-19 study in the United States. 
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2.1 Study Design and Participants 
A prospective combined cohort study was carried out in the MACS and WIHS centers in 
the United States as part of a collective MWCCS COVID-19 study. Information was collected 
from April 2020 until September 2020 in 21 sites across the United States (see fig. 1). The study 
followed enrolled participants through 3 parts: baseline assessment, follow-up 1 and follow-up 2.  
Interviews were collected remotely via phone, and data collected was entered into GEMINI 
systems, the MACS/WIHS CCS data management system. Data collected was stored in the 
database developed by the MWCCS Data Analysis and Coordinating Center (DACC) managed by 
Johns Hopkins University School of Public Health. The total participation was for baseline: 3416, 
follow-up 1: 3389, follow-up 2: 3273. Phone interviews were conducted in 4–6-week intervals, 
allowing at least 30 days between each questionnaire. All participants were consented before the 
interview and forms were consistent for all sites in the study. Participants were identified by 
assigned identification (ID) numbers and were entered into the system by their number. HIV status 
was designated by ID number, and confirmed during the interview. The duration of each interview 
was between 15-45 minutes, and additional questionnaires were added to follow-up 1 and follow-
up 2 questionnaires. These questionnaires were separate from the COVID forms and were 
conducted in each follow-up interview to assess food insecurity and substance use changes during 
the pandemic. 
The population of participants were divided into HIV- and HIV+ groupings. Baseline 
interviews included questions related to clinical symptoms, concurrently existing symptoms, 
severity of reported symptoms, potential exposures, reasons for testing, HIV status, any current 
antiretroviral therapies and adherence, access to healthcare, tobacco use or exposure to tobacco 
use, physical, sexual, or emotional abuse, and psychosocial impacts of the pandemic. The baseline 
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questionnaire asked participants to recall any symptoms as well as the duration of those symptoms 
since January 2020. The interviews asked participants to divulge information about adherence to 
public health guidelines, social distancing, and specific actions taken to prevent spread of COVID-
19. If participant answered “yes” to diagnostic testing for COVID-19, further inquiry into type of 
collection (mouth or throat swab, nasal swab, blood test, or saliva collection) proceeded. The test 
result was confirmed with the reported testing site in most cases. Follow-up interviews were 
similar in structure but did not include questions about antiretroviral therapies and date in which 
they were prescribed, if any, for PLWH, blood pressure medications ending in “-pril” or “-sartan” 
or of living situations and homelessness. Both follow-up interviews asked participants to recall 
symptoms since the previous interview, anywhere from 6 to 8 weeks before. Provider information 
was collected for participants tested for COVID-19, prescribed treatment, and/or were hospitalized 




Testing and SARS-CoV-2 positivity levels of HIV negative and HIV positive groups were 
identified in each interview category (baseline, follow-up 1, and follow-up 2). A total of 3416 
(N=3416) baseline interviews were conducted in all sites. 3389 (N=3389) interviews were 
conducted in the first “wave” of follow-ups and 3273 (N=3273) were conducted in the “second” 
wave of follow-up interviews among all sites. 2082 HIV+ (60.9%) and 1334 HIV- (39.1%) 
participant interviews were reported for the initial wave of baseline interviews. A total of 2064 
and 1962 of  HIV+ participants were interviewed for follow-ups 1 and 2 respectively. 1325 and 
1311 interviews for HIV- participants were conducted for follow-ups 1 and 2 respectively. Other 
demographic information such as age, BMI, known comorbidity, occupation, tobacco use, living 
arrangements, and other information is independent of this data, and was inaccessible at the time 
of this analysis. 
Of interviews conducted in all sites during baseline questionnaire administration, 280 
(N=280) HIV+ and 171 (N=171) HIV- participants were tested for COVID-19. After the first 
follow-up “wave”, 403 (N=403) HIV+ and 240 (N=240) HIV- participants were tested. Finally, 
during the second follow-up “wave”, 470 (N=470) HIV+ and 299 (N=299) HIV- were tested.  
Among the participants with HIV diagnosis, 31 participants had a positive test for COVID-19 
during baseline interviews, while 10 participants without HIV diagnosis tested positive for 
COVID-19. In the follow-up interviews, those with HIV diagnosis tested for COVID-19, 26 tested 
positive during the first “wave” of follow-ups while 25 tested positive during the second “wave” 
of follow-ups. In those without HIV diagnosis tested for COVID-19, 10 participants tested positive 
in the first “wave”, and 9 tested positive in the second “wave”.  
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During baseline interviews, 37 HIV+ and 21 HIV- participants reported hospitalization for 
COVID-19 related illness. Twenty-seven HIV+ and 12 HIV- participants reported hospitalizations 
for COVID-19 diagnosis during follow-up interviews.  
 
Table 1: Baseline, follow-up 1 and follow-up 2 interviews and COVID-19 testing data collected based on HIV 
status. 












Baseline HIV+ 2082 1802 280 248 31 
 
HIV- 1334 1163 171 159 10 
Follow-up 1 HIV+ 2064 1661 403 367 26 
 
HIV- 1325 1085 240 227 10 
Follow-up 2 HIV+ 1962 2365 470 440 25 
 
HIV- 1311 1551 299 282 9 
 
3.1 Comparison of COVID-19 Diagnosis 
Figure 2 presents the analysis of COVID-19 rates among those that tested positive. Rates 
were calculated as percentages, where: 7% of HIV+ and 2% of HIV- rate of infection in the 
baseline assessment, 4 % of HIV+ and 2% rate in follow-up 1, and 3% of HIV+ and 1% of HIV- 




Figure 2: Positivity rates among HIV+ and HIV- participants during each interview phase confirmed and 
reported by each site. 
 
Figure 3 presents the analysis of COVID-19 infection rates in all participants that were 
tested for COVID-19. This graph shows the percent of positive and negative test results among 
HIV+ and HIV- groups, however it is necessary to point out the rate of testing is higher in the 
HIV+ group than in the HIV- group.  
A Chi squared test was performed for the categorical group analysis to determine whether 
there is a significant correlation between HIV+ status and COVID-19 positive rates, and if these 
rates change in each “wave” of interviews (Tables 2-4). The analysis performed resulted in these 
statistical conclusions at р < .05. Х2 (1, N=448) = 3.415, р=.065 at baseline, Х2 (1, N=630) = 1.576, 
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of independence indicated there was no significant association between HIV+ individuals and 
COVID-19 diagnosis in any category.  
A Chi squared test was then performed to determine if overall, correlation existed among 
each wave if considered collectively (Table 5). The results of the analysis determined, at p<.05, 
Х2 (1, N=1834) =7.075, p=.0078. For all interviews, a chi-squared test of independence showed 
that there was significance between HIV+ individuals and COVID-19 diagnosis overall.  
 
Table 2: Chi squared calculation and significnace level at p < 0.05  for baseline interviews. 







P value  
Baseline HIV+ 31 248 3.145 .065 
 
HIV- 10 159   
 
Table 3: Chi squared calculation and significance level at p<0.05 for follow-up 1 interviews. 







P value  
Follow-1 HIV+ 26 367 1.576 .209 
 







Table 4: Chi squared calculation and significance level at p<0.05 for follow up 2 interviews. 







P value  
Follow-2 HIV+ 25 440 2.173 .140 
 
HIV- 9 282   
 
Table 5: Chi sqared calculation and significance level at p<0.05 for all categories of interviews. 











HIV+ 82 1055 7.075 .0078 
 
HIV- 29 668   
 
The proportion of participants reporting positive COVID-19 tests did not vary by HIV 
status in each interview wave, nor did it differ by the timeframe of interview during early and 
middle stages of the pandemic. Based on the collected data, there is no significant evidence to 
suggest that correlation exists between the subgroups, and other potential confounding factors 
should be considered. However, if all interview waves are considered, there is a significant 
relationship between HIV positive status and COVID-19 positive diagnosis compared to the 
seronegative group. This is a considerable correlation, and concludes that overall, there is 
significance in the analysis. This could be due to the larger sample size in each category and higher 




Figure 3: Results of all three "waves" of interviews and final total. Participants with and without HIV 
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4.0  Discussion 
The goal of this analysis was to look at the overall correlation between HIV status and COVID-19 
diagnosis. The study was able to isolate PLWH and those without HIV diagnosis participants to 
provide indication of possible coinfection or heightened risk for coinfection during peak COVID-
19 transmission rates throughout the United States, despite stringent public health regulations put 
into place by federal, state, and local departments. This analysis showed that there was no 
significant relationship between HIV+ and HIV- groups and lab diagnosed SARS-CoV-2 infection 
reported by participants and confirmed by reported testing site during each interview wave. 
Overall, there is a significant association between HIV positive status and COVID-19 diagnosis 
between April and September 2020 when reported diagnoses were considered collectively. 
Therefore, the study points to a greater impact over the course of the pandemic, or while interviews 
were taking place, demonstrating potential for PLWH to be at an increased risk for SARS-CoV-2 
infection. However, this analysis looks primarily at HIV status and COVID-19 test results, separate 
from other factors such as accessibility to testing, geographical location, or other demographics 
that may represent potential differences in outcomes. Adjustments can be made for these factors, 
resulting in more accurate identification of independent predictors (Etienne, 2020).  
Diagnostic testing of SARS-CoV-2 infection via nasopharyngeal or oral swab are the most 
common and effective methods of testing, especially for active infections. However, availability 
of diagnostic kits utilizing reverse transcription polymerase chain reaction (RT-PCR) for viral 
RNA detection were widely unavailable during the first months of the COVID-19 pandemic 
(Beeching, 2020). Less than 0.01 per 1000 people were tested each day in early March 2020, 
compared to 2.57 per 1000 people that were tested at the end of August 2020 (Hasell, 2020). 
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Asymptomatic carriers or those without severe symptoms were frequently turned away from 
testing to ultimately preserve diagnostic tests for individuals with more severe symptoms. This 
increased the frequency of infections, while the delay in availability both promoted transmissions 
and decreased possible diagnoses (WHO, 2020).  Long wait times for results, potential for false 
negative readings, inaccuracy and low sensitivity of “rapid” testing, and significant stress on 
healthcare and medical lab workers increased potential exposure time to others, especially those 
with mild symptoms. The demand for testing kits continues to outweigh the supply, causing 
healthcare prioritizing to those working directly with compromised hospital or long-term facility 
patients, vulnerable individuals in hospitals or long-term facilities, and those with active symptoms 
consistent with SAR-CoV-2 infection. To compensate for lack of available tests, especially in areas 
of high demand, strict public health guidelines were put in place to prevent unnecessary testing, 
thwart further community spread, and to help control overwhelmed hospital systems (WHO, 
2021). Thus, discouragement from public health and healthcare authority to utilize testing unless 
experiencing severe illness or have known contact with another with confirmed positive test result 
and overall lack of testing in general may be a contributing factor to low rates of testing in these 
groups, and could be an indication of potentially undocumented rates of positivity in the study. 
To monitor the progression of the pandemic, it is incredibly important to determine the positivity 
rate as it reflects the number of tests being performed in the community, but also could indicate 
who is prioritized for testing dependent on available tests. High positivity rates may indicate more 
testing patients with severe illness in a population, leaving out those who may be tested without 
symptoms. However, lower positivity rates may reflect a population where insufficient testing is 
being performed, or that testing is available to those who want to be tested with mild or no 
symptoms. If testing is sufficient, then positivity rates should hover in the 4-5% range for at least 
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14 days but should not be the determinant factor for lifting or changing public health guidelines 
(Johns Hopkins University of Medicine, 2021). The United States population positivity rates of 
COVID-19 during mid-April of 2020 was around 21.3%, compared to 6% mid-May, 3.9% mid-
June, 6.8% mid-July, and 6.10% mid-August (Hassell, 2020). This sudden decrease can be 
attributed to increase in public information about the virus, public health mitigations such as stay-
at-home orders, mask mandates, and closure of public and private gathering spaces nationally by 
April 2020. The jump in positivity rates from June to July reflect loosening of state and local laws 
during periods of low incidence rates, which ultimately caused spikes in reported COVID-19 cases 
across the United States. However, the positivity rate for PLWH study participants is 
comparatively similar to that of the general public during the first and second wave of interviews 
(about 9% higher), but is almost half the rate in the third wave of interviews (between July and 
August 2020). The rate for participants without HIV diagnosis is about 70-80% less than the 
general population, which may explain the need to control for other factors in each group. 
4.1 Limitations 
Some issues arising in this study are in part due to the lack of demographic, geographic, 
and medical information to address potential confounding variables. Although appropriate controls 
were used, a deeper analysis may explain the possible low positivity rate, testing availability issues 
at the beginning of the pandemic, and behavior changes according to changing public health 
response and concern for those with underlying health conditions. Understanding of COVID-19 
and the manifestation of the disease itself is an important yet limiting factor of the study. Although 
some participants mentioned experiencing mild symptoms consistent with COVID-19 diagnosis, 
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most were not tested during the symptomatic period. Lack of apparent knowledge of where to 
receive testing and lack of testing in general may also factor into the low testing rate among 
participants especially during baseline interviews.  Also, consideration of ART adherence and 
overall use of ART could also be an important factor in determining if positivity rates were higher 
or lower among those on ART or cART. Thus, actual disease prevalence may have gone untraced 
during the interview stage, and could be much higher than confirmed by this cohort study.  
4.2 Conclusion and Further Direction 
This preliminary analysis concluded that there is not significant association between 
COVID-19 infection rates and HIV positive status for participants in any discrete timeframe that 
the interviews were administered, however, if considered collectively, an association between HIV 
positive status and COVID-19 diagnosis can be determined in this combined cohort study. There 
is not enough evidence to conclude that COVID-19 infections are higher in the HIV+ group 
compared to the HIV- group when isolated from other confounding factors in each wave of 
interview administration. It is important to clarify that other factors identified through this study 
may have an effect on overall interpretations of this data, and could give a more refined explanation 
for the findings of this research. Factors such as age, sex, race, geographic location, underlying 
conditions, and adherence to ART should be considered in further analyses of this data, and could 
describe the risk factors for SARS-CoV-2 infection. Further direction of this study could identify 
these potential risk factors for those with HIV diagnosis and whether HIV positive individuals are 
more or less likely to adhere to public health guidelines, receive vaccinations when available, and 
voluntarily receive testing for COVID-19. Inclusion of these variables could shed light on the 
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COVID-19 pandemic, increase knowledge and understanding of the disease, and ultimately 
improve the quality of life for people living with HIV. Overall, the public health impact of this 
study can aid in understanding the implications of global pandemics and epidemics, assist medical 
professionals in diagnosing and understanding the risk factors of SARS-CoV-2 infection in 




Appendix A D’Souza et al. supplementary figures 
Appendix Table 1: MWCCS partcipant characteristic completing COVID-19 survey by sex and HIV 
serostatus (D’Souza et al., 2020). 
 






Characteristics PLWH SN PLWH SN 
 N=3411 N=3411 N=788 N=798 N=1290 N=535 
Date of survey administration       
April 8-30 791 23 7 13 36 31 
May 1-31 2157 63 68 72 56 61 
June 1-30 463 14 25 15 8 8 
Race and Ethnicity       
Black, non-Hispanic 1637 48 26 15 71 74 
Hispanic, any race 454 13 17 7 14 15 
White, non-Hispanic 1224 36 55 77 11 6 
Other, non-Hispanic 96 3 2 1 3 5 
Region of US        
West (California) 824 24 38 38 12 13 
Northeast (New York)& 524 15 0 0 28 31 
Mid-Atlantic (Washington DC, Maryland, 
Pennsylvania) 
965 28 41 50 13 14 
South (Alabama, Florida, Georgia, 
Mississippi, and North Carolina)& 
624 18 0 0 36 31 
Midwest (Illinois, Ohio) 474 14 21 11 12 11 
Where are you living now?       
In your own house/apartment 2979 87 87 93 87 81 
At parent’s/someone else's house/apartment 344 10 10 5 10 16 
Other living arrangement+ 87 3 3 2 3 3 
Number of people who live with you       
0 1132 33 39 41 30 20 
1 1244 36 42 48 30 27 
2 467 14 11 7 17 19 
≥3 566 17 8 4 23 34 
Current tobacco and marijuana use       
Smoke tobacco 808 24 19 11 30 35 
Vape tobacco 55 2 2 2 2 2 
Use marijuana (smoke, vape or dab) 738 22 29 20 18 23 
Anyone who smokes tobacco in your shared 
living space 
533 16 14 9 18 23 





















NA <20  
(<20, 22) 
NA 
Currently taking any antiretroviral medications* 2078 95 95 NA 95 NA 
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Appendix Table 2. Social distancing practices and other public health guideline following reported by 
partcipants (D’Souza, et al, 2020). 
 
 
Appendix Table 3: Social distancing mandates in place during interviews from April-June 2020 at each site 
(D’Souza et al., 2020). 
 
Practices used to prevent the spread of SARS-CoV-2 
infection 
Percent P- 
value All PLWH SN 
 N=3411 N=2078 N=1333 
Staying home as much as possible 97 97 97 0.32 
Social distancing (6 ft) 98 98 98 0.98 
Self-isolating due to symptoms or positive test 2 3 2 0.10 
Self- isolating due to exposure to infected person 2 2 2 0.38 
Self- isolating due to being unsure of infection status 5 5 6 0.67 
Not making changes to daily life and routine~ 13 15 11 0.003 
Taking other steps (additional self-reported answers) 75 73 79 <.001 
Other*: gloves 22 23 22 0.69 
Other*: masks 62 60 66 <.001 
Other*: using disinfectant, washing hands and surfaces 34 33 35 0.27 
Other*: no visitors, not going out, ordering food, ordering 
grocery delivery 
2 3 2 0.35 
 
Study Site Date range (year=2020) Date Started (year=2020) 






Re-opening Start Date^ 
Phase 1  
 
Phase 2  Phase 3  
WEST       
Los Angeles, CA 04/24-06/19 3/20-5/7 3/16 5/8 6/12 TBD 
San Francisco, CA 04/23-06/18 3/19-5/16 3/17 5/17 6/1 TBD 
NORTHEAST       
Bronx, NY  04/21-06/16 3/20-5/15 3/20 6/8 6/22 7/6 
Brooklyn, NY  04/22-06/11 3/20-5/15 3/20 6/8 6/22 7/6 
MID-ATLANTIC       
Baltimore, MD 05/01-06/25 3/30-5/15 3/16 5/15 6/5 TBD 
Washington D.C. 04/30-06/18 04/01- 06/08 3/16 5/29 6/22 TBD 
SOUTH       
Miami, FL  04/16-06/10 4/1-4/30 3/24 5/4 6/5 7/13 
Atlanta, GA  04/23-06/18 4/2-4/30 4/23 5/1 5/27 6/11 
Chapel Hill, NC 04/21-06/22 3/27-5/8 3/12 5/8 5/22 TBD 
Birmingham, AL 04/20-05/22 3/16-4/30 3/16 5/22 7/3 TBD 
Jackson, MS 05/01-05/29 4/1-5/3 4/1 5/4 6/1 TBD 
MIDWEST       
Chicago, IL 05/11-06/30 (men) 
04/08-06/05(women) 
3/20-5/29 3/26 6/3 6/26 TBD 
Pittsburgh, PA 04/20-06/30 4/1-5/8 3/12 5/8 5/12 TBD 
Columbus, OH 04/20-06/30 3/22-5/1 3/10 5/4 6/5 TBD 
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Appendix Figure 1: Interview questionnaire examples from baseline interview. Interviewer markered “0” for 
no, “1” for yes, and completed other survey questions based on reported answers from participants. 
Participants were asked questions about symptoms and duration, testing, public health guidelines and 
practice, ART adherence, household density, smoking habits, and prescribed blood pressure medications. 
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